EcoDrugPlus

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSDARG00000003584
Gene Symbol: PLA2G7
5 Enzyme and pathways 5 Cross references
206 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSDARG00000101089
Gene Symbol: GART
4 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Plasminogen

Ensembl ID : ENSDARG00000023111
Gene Symbol: PLG
17 Enzyme and pathways 5 Cross references
255 Possible Orthologues:

Plasminogen Activator, Tissue

Ensembl ID : ENSDARG00000062707
Gene Symbol: PLAT
5 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Platelet-Activating Factor Receptor

Ensembl ID : ENSDARG00000042370
Gene Symbol: PTAFR
9 Enzyme and pathways 5 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Beta Polypeptide B

Ensembl ID : ENSDARG00000038139
Gene Symbol: PDGFBB
5 Cross references
194 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Alpha Polypeptide

Ensembl ID : ENSDARG00000070494
Gene Symbol: PDGFRA
14 Enzyme and pathways 5 Cross references
204 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSDARG00000100897
Gene Symbol: PDGFRB
14 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Polo-Like Kinase 4 (Drosophila)

Ensembl ID : ENSDARG00000004576
Gene Symbol: PLK4
16 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 1

Ensembl ID : ENSDARG00000019529
Gene Symbol: PARP1
26 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSDARG00000079202
Gene Symbol: PARP2
13 Enzyme and pathways 5 Cross references
186 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSDARG00000003961
Gene Symbol: PARP3
5 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).